Replies to post #27478 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Opportunity, I don't care if you agree with me or not. I am just stating the facts that it appears that Moro has changed his mind about taking RECAF into clinical trials on his own.

Read the quote below. It is new wording by Moro and not just a cut and paste from earlier filings. It says absolutely NOTHING about the company getting a RECAF product FDA approved. However, it does now clearly state that the partners or licensees would do the regulatory functions.

I am just agreeing with Moro that it is probably a more cost effective use of his current cash.

From the 10Q filed August 15, 2010:

"Our business model is to develop internally our RECAF cancer diagnostic
platform to the stage where individual applications can be partnered or licensed
in strategic relationships for regulatory approval and commercialization.

Our
objective is to receive cash from licensing fees, milestone payments, and
royalties from such partnerships which support continued development of our
cancer diagnostic portfolio. We have signed licensing agreements for its cancer
detection blood tests with Abbott Laboratories and with Inverness Medical
Innovations. In the veterinarian market where there are no regulatory hurdles,
our objective is to commercialize our technology through our subsidiary, OncoPet
Diagnostics, and with distributors in North America, Europe and elsewhere.

Our principal objectives for the twelve-month period ending June 30, 2011
are as follows:

o grant one additional license for our cancer detection blood test;
o commercialize veterinary applications of RECAF testing technology through our wholly-owned subsidiary, OncoPet Diagnostics;
o finish development for our rapid, point of care cancer test; and

[Gold Seeker]

Opportunity, your attempt to get Moro to spend money on clinical trials and FDA submissions appear to be motivated by your desire for a short term pump of the stock price.

Do you want Moro to use a bunch of his money in an attempt to gain FDA approval and then have to dilute the stock again much sooner.

You never know, Moro might spend a ton of money on a submisson and then have the FDA request more data. Nothing is a sure thing when the FDA is involved.

In this case, I side with Moro and not yuo.